Six years ago, Eli was founded on a bold idea: what if hormones could be measured in real time without a lab, without delay, anytime and anywhere?
That vision is now a reality. We’ve raised $12M USD in Series A funding to scale that vision. The round was led by BDC Capital’s Thrive Venture Fund, with participation from Muse Capital, TELUS Global Ventures, and other investors who share our belief that hormone health is the next frontier in personalized care.
The fundraise brings our total capital raised to $20M.
The context.
Hormones power nearly everything: stress, energy, recovery, mood, focus, sleep, fertility, performance, and longevity. But most of us have no idea what our hormones are doing. We’re flying blind.
Traditional testing is built for snapshots: a single point in time, captured in a lab, days or weeks after symptoms show up. But hormones shift constantly. Cortisol, for example, fluctuates by the hour. One-time tests can help, but they miss the bigger picture. What we need is a live feed.
The problem.
Hormone imbalances are widespread, underdiagnosed, and often addressed only after years of symptoms. The data makes that clear:
-
1 in 3 adults show signs of cortisol dysregulation
-
60% of adults will experience symptoms related to hormone imbalances
Despite how common these issues are, the tools to understand our hormones in real time haven’t existed until now.
The solution.
Eli has built what was missing: a way to track hormones instantly using just saliva and your phone. This empowers people to connect symptoms with real-time hormone changes and take action sooner.
The technology.
Eli isn’t just a consumer health brand. We’ve built deep technology to build the real-time interface to the human body,making instant hormone monitoring possible.
HormometerTM is built on:
-
Biochemistry designed for microfluidics.
-
AI and machine learning to interpret dynamic hormone signals.
-
Custom hardware, manufactured in-house.
-
12+ patent-pending innovations across science, engineering, and design.
After nearly six years of R&D, we’ve reached commercial readiness. We’ve completed third-party validations. And our private beta is live (at the time of writing), with early adopters are already usingHormometer™ as part of their daily health routines.
What’s next?
With this raise, we’re scaling manufacturing, expanding access, and unlocking more biomarkers, beginning with cortisol and progesterone. Public launch is targeted for later in 2025. This is just the start of a new era in hormone health.
Read more about the fundraise at Axios, Fitt Insider, Femtech Insider, BetaKit, and Athletec News.
